2 citations
,
February 2014 in “Journal of Crohn's and colitis” This study observed that 6.45% of IBD patients treated with anti-TNF therapy developed severe psoriasiform reactions, with notable cases of alopecia universalis suggesting a potential link to previous alopecia areata.
January 2026 in “Journal of Crohn s and Colitis” This study found that high-dose intravenous iron therapy was effective and safe for patients with inflammatory bowel disease-associated anemia, improving hemoglobin and iron levels, reducing inflammation markers, and alleviating disease activity and symptoms, even in those with active inflammation.
February 2018 in “The American Journal of Gastroenterology” This study observed that intravenous ferric carboxymaltose did not inhibit the drug-induced reduction of inflammatory activity in patients with inflammatory bowel disease, as indicated by lower CRP levels.
January 2018 in “Journal of Crohn s and Colitis” This study found that high-dose intravenous ferric carboxymaltose may reduce inflammatory activity in patients with inflammatory bowel disease and iron deficiency anaemia, as evidenced by decreased CRP levels and improved clinical disease indices.
278 citations
,
March 2013 in “Gut” In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.